{
    "pmcid": "11054741",
    "qa_pairs": {
        "What advantage do nanobodies have over traditional antibodies in targeting the spike protein of SARS-CoV-2?": [
            "Their small size and ability to bind to cryptic epitopes",
            "Their ability to induce a stronger immune response",
            "Their longer half-life in the bloodstream",
            "Their ability to be produced in larger quantities"
        ],
        "What is the primary target of the engineered nanobodies discussed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What mechanism allows multivalent nanobodies to enhance neutralization efficacy against SARS-CoV-2 variants?": [
            "Simultaneous binding to multiple RBDs",
            "Inhibition of viral replication",
            "Blocking of viral RNA synthesis",
            "Disruption of viral assembly"
        ],
        "What was the geometric mean IC50 of the most potent multivalent nanobody, B13-B13-B13, against all tested pseudoviruses?": [
            "20.83 ng/mL",
            "50.12 ng/mL",
            "10.45 ng/mL",
            "35.67 ng/mL"
        ],
        "Which nanobody demonstrated broad-spectrum neutralization against multiple Omicron subvariants including BQ.1.1 and XBB.1?": [
            "A14",
            "B13",
            "C21",
            "D5"
        ]
    }
}